EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients.
How EY can help
-
Our Forensics Government Pharma Pricing Program team can help navigate complex government rules and regulations, including Medicaidand Product Returns.
Read more -
EY Government Contract Services provides government contracting consulting, government contract accounting and pharmaceutical government pricing support.
Read more
340B covered entities focus a lot of compliance efforts on parts of the program governed by the Health Services and Resources Administration (HRSA), but is enough attention being given to non-HRSA compliance obligations? These obligations include:
Medicaid risks
Beyond duplicate discount prevention, state Medicaid programs often impose challenging and cumbersome 340B-specific billing obligations on covered entities. Billing Medicaid incorrectly can cause you to receive Medicaid dollars you are not otherwise entitled to. Billing Medicaid correctly is difficult because each state can have different billing rules, and rules can even differ between retail and institutional settings. What’s more, seemingly small errors on government programs can cause you big problems.
340B covered entities should consider the following when evaluating340B drug billings to Medicaid payers:
- What steps are you taking to mitigate your risk (e.g., third-party audit)?
- What states are you billing and what are their rules for 340B drugs?
- What systems and/or vendors are responsible for making sure that your Medicaid bills are built correctly?
- Are you keeping up on your institutional and retail pharmacy risks related to Medicaid billing?
- What operational and procedural challenges are you facing to comply with 340B Medicaid rules?
Medicare
Medicare’s 340B rules are consistent from state to state but have recently been in flux, which may cause uncertainty about billing obligations and associated risks. Additionally, recent Medicare changes offer financial opportunities that covered entities might not be leveraging.
340B covered entities should consider the following when evaluating their 340B Medicare risk:
- What processes are in place to establish that your Medicare charges are built correctly?
- What efforts have you taken to recover underpayments from Medicare Part B and Medicare Advantage Plans?
- Is access to 340B pricing a factor your covered entity generally considers when enrolling in Medicare reimbursement programs?